Select language
English
English German Spanish Italian French

General

Lupin Neurosciences is committed to working with Healthcare Professionals to develop science-based solutions that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.
Portfolio
  • NaMuscla®
    • Pipeline
  • Overview
    • Publications
  • 2023 Congresses
  • 2024 Congresses
  • 2025 Congresses
  • 2026 Congresses
    • General
  • Medical Inquiries & Adverse Event Reporting
  • Transparency Reporting
    • 10th Congress of the European Academy of Neurology, Helsinki, Finland, 21-24 June 2025
    Myotonic disorders

    EPO-465
    Mexiletine Paediatric Investigation Plan, PIP 4 Study: Efficacy findings in children aged 0-<18 years with myotonia
    Christine Barnérias; Arnaud Isapof; Jean-Yves Hogrel; Nikki Adetoro; Alla Zozulya-Weidenfeller
    Poster

    EPO-466
    Mexiletine Paediatric Investigation Plan, PIP4 study: safety and pharmacokinetic findings in children with myotonia
    Christine Barnérias; Arnaud Isapof; Helen Pentikis; Nikki Adetoro; Alla Zozulya-Weidenfeller
    Poster

    Non-dystrophic myotonia

    EPO 471
    Real-world patient-reported outcomes in NDM show consistent myotonia improvements with mexiletine
    Emma Matthews; Savine Vicart; Vinojini Vivekanandam; Saam Sedehizadeh; Angela Rosenbohm; Celine Tard; Dipa Jayaseelan; Christiane Schneider-Gold; Jean-Yves Hogrel; Alla Zozulya-Weidenfeller
    Poster

    EPV-644
    Development and validation of the Myotonia Symptom Checker: A novel tool to raise public awareness of myotonia
    Yann Péréon; Cristina Dominguez-Gonzalez; Linda Edmondson; Irina Fingerhut; Tiziana-Enrica Mongini; Marija Roddate; Janet Stone; Rob Wyer; Alla Zozulya-Weidenfeller
    Poster